The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.
- DOI
- 10.1016/s2468-1253(26)00130-5
- Published
- 2026 Oct
- Container
- The lancet. Gastroenterology & hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2468-1253-26-00130-5,
title = {The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.},
author = {Noureddin M and Dunn W and Patil R and Desai D and Puskoor R and Shin J and To D and Bell AC and Lee DR and Lin YH and Lee S},
year = {2026},
journal = {The lancet. Gastroenterology \& hepatology},
doi = {10.1016/s2468-1253(26)00130-5},
url = {https://doi.org/10.1016/s2468-1253(26)00130-5}
}RIS
TY - JOUR TI - The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial. AU - Noureddin M AU - Dunn W AU - Patil R AU - Desai D AU - Puskoor R AU - Shin J AU - To D AU - Bell AC AU - Lee DR AU - Lin YH AU - Lee S PY - 2026 JO - The lancet. Gastroenterology & hepatology DO - 10.1016/s2468-1253(26)00130-5 UR - https://doi.org/10.1016/s2468-1253(26)00130-5 ER -
APA
M, N., W, D., R, P., D, D., R, P., J, S., D, T., AC, B., DR, L., YH, L., & S, L. (2026). The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.. The lancet. Gastroenterology & hepatology. https://doi.org/10.1016/s2468-1253(26)00130-5
Source records
- pubmed · retrieved 2026-11-11T01:48:33.945Z